Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial

Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antimalarials / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic
  • Drug Combinations
  • Drug Repositioning
  • Drug Synergism
  • Humans
  • Hydroxychloroquine / therapeutic use*
  • SARS-CoV-2 / pathogenicity*
  • Statistics as Topic
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antimalarials
  • Antiviral Agents
  • Drug Combinations
  • Hydroxychloroquine
  • Azithromycin